Emerging Role of Sphingolipids and Extracellular Vesicles in Development and Therapeutics of Cardiovascular Diseases

Overview

Journal Int J Cardiol Heart Vasc

Date 2024 Aug 14

PMID 39139609

Authors

Owais Mohmad Bhat

Rakeeb Ahmad Mir

Iqra Bashir Nehvi

Nissar Ahmad Wani

Abid Hamid Dar

M Afzal Zargar

Affiliations

Soon will be listed here.

Abstract

Sphingolipids are eighteen carbon alcohol lipids synthesized from non-sphingolipid precursors in the endoplasmic reticulum (ER). The sphingolipids serve as precursors for a vast range of moieties found in our cells that play a critical role in various cellular processes, including cell division, senescence, migration, differentiation, apoptosis, pyroptosis, autophagy, nutrition intake, metabolism, and protein synthesis. In CVDs, different subclasses of sphingolipids and other derived molecules such as sphingomyelin (SM), ceramides (CERs), and sphingosine-1-phosphate (S1P) are directly related to diabetic cardiomyopathy, dilated cardiomyopathy, myocarditis, ischemic heart disease (IHD), hypertension, and atherogenesis. Several genome-wide association studies showed an association between genetic variations in sphingolipid pathway genes and the risk of CVDs. The sphingolipid pathway plays an important role in the biogenesis and secretion of exosomes. Small extracellular vesicles (sEVs)/ exosomes have recently been found as possible indicators for the onset of CVDs, linking various cellular signaling pathways that contribute to the disease progression. Important features of EVs like biocompatibility, and crossing of biological barriers can improve the pharmacokinetics of drugs and will be exploited to develop next-generation drug delivery systems. In this review, we have comprehensively discussed the role of sphingolipids, and sphingolipid metabolites in the development of CVDs. In addition, concise deliberations were laid to discuss the role of sEVs/exosomes in regulating the pathophysiological processes of CVDs and the exosomes as therapeutic targets.

References

Xiao J, Pan Y, Li X, Yang X, Feng Y, Tan H . Cardiac progenitor cell-derived exosomes prevent cardiomyocytes apoptosis through exosomal miR-21 by targeting PDCD4. Cell Death Dis. 2016; 7(6):e2277. PMC: 5143405. DOI: 10.1038/cddis.2016.181. View

Wang X, Morelli M, Matarese A, Sardu C, Santulli G . Cardiomyocyte-derived exosomal microRNA-92a mediates post-ischemic myofibroblast activation both in vitro and ex vivo. ESC Heart Fail. 2020; 7(1):284-288. PMC: 7083461. DOI: 10.1002/ehf2.12584. View

Ray K, Wright R, Kallend D, Koenig W, Leiter L, Raal F . Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020; 382(16):1507-1519. DOI: 10.1056/NEJMoa1912387. View

El Andaloussi S, Mager I, Breakefield X, Wood M . Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12(5):347-57. DOI: 10.1038/nrd3978. View

Park T, Hu Y, Noh H, Drosatos K, Okajima K, Buchanan J . Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res. 2008; 49(10):2101-12. PMC: 2533410. DOI: 10.1194/jlr.M800147-JLR200. View

Ashraf M, Kar N, Podrez E . Oxidized phospholipids: biomarker for cardiovascular diseases. Int J Biochem Cell Biol. 2008; 41(6):1241-4. PMC: 2685718. DOI: 10.1016/j.biocel.2008.11.002. View

Maceyka M, Spiegel S . Sphingolipid metabolites in inflammatory disease. Nature. 2014; 510(7503):58-67. PMC: 4320971. DOI: 10.1038/nature13475. View

Borodzicz S, Czarzasta K, Kuch M, Cudnoch-Jedrzejewska A . Sphingolipids in cardiovascular diseases and metabolic disorders. Lipids Health Dis. 2015; 14:55. PMC: 4470334. DOI: 10.1186/s12944-015-0053-y. View

Testai F, Kilkus J, Berdyshev E, Gorshkova I, Natarajan V, Dawson G . Multiple sphingolipid abnormalities following cerebral microendothelial hypoxia. J Neurochem. 2014; 131(4):530-40. PMC: 4349382. DOI: 10.1111/jnc.12836. View

10.

Mohan A, Singh R, Kumari M, Garg D, Upadhyay A, Ecelbarger C . Urinary Exosomal microRNA-451-5p Is a Potential Early Biomarker of Diabetic Nephropathy in Rats. PLoS One. 2016; 11(4):e0154055. PMC: 4839711. DOI: 10.1371/journal.pone.0154055. View

11.

Barile L, Vassalli G . Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol Ther. 2017; 174:63-78. DOI: 10.1016/j.pharmthera.2017.02.020. View

12.

Boini K, Xia M, Koka S, Gehr T, Li P . Sphingolipids in obesity and related complications. Front Biosci (Landmark Ed). 2016; 22(1):96-116. PMC: 5844360. DOI: 10.2741/4474. View

13.

Kucharzewska P, Belting M . Emerging roles of extracellular vesicles in the adaptive response of tumour cells to microenvironmental stress. J Extracell Vesicles. 2013; 2. PMC: 3760648. DOI: 10.3402/jev.v2i0.20304. View

14.

Peters L, Kuebler W, Simmons S . Sphingolipids in Atherosclerosis: Chimeras in Structure and Function. Int J Mol Sci. 2022; 23(19). PMC: 9570378. DOI: 10.3390/ijms231911948. View

15.

Dinkins M, Wang G, Bieberich E . Sphingolipid-Enriched Extracellular Vesicles and Alzheimer's Disease: A Decade of Research. J Alzheimers Dis. 2016; 60(3):757-768. PMC: 5360538. DOI: 10.3233/JAD-160567. View

16.

Wu X, Zhang H, Qi W, Zhang Y, Li J, Li Z . Nicotine promotes atherosclerosis via ROS-NLRP3-mediated endothelial cell pyroptosis. Cell Death Dis. 2018; 9(2):171. PMC: 5833729. DOI: 10.1038/s41419-017-0257-3. View

17.

Yang Y, Yin J, Baumgartner W, Samapati R, Solymosi E, Reppien E . Platelet-activating factor reduces endothelial nitric oxide production: role of acid sphingomyelinase. Eur Respir J. 2009; 36(2):417-27. DOI: 10.1183/09031936.00095609. View

18.

Van Rooij E, Olson E . MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov. 2012; 11(11):860-72. PMC: 6813819. DOI: 10.1038/nrd3864. View

19.

Meissner A, Miro F, Jimenez-Altayo F, Jurado A, Vila E, Planas A . Sphingosine-1-phosphate signalling-a key player in the pathogenesis of Angiotensin II-induced hypertension. Cardiovasc Res. 2017; 113(2):123-133. DOI: 10.1093/cvr/cvw256. View

20.

Yu M, Song W, Tian F, Dai Z, Zhu Q, Ahmad E . Temperature- and rigidity-mediated rapid transport of lipid nanovesicles in hydrogels. Proc Natl Acad Sci U S A. 2019; 116(12):5362-5369. PMC: 6431219. DOI: 10.1073/pnas.1818924116. View